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Objectives This study sought to assess the acute hemodynamic effect of vasopressin V2 receptor antagonism.
Background In decompensated heart failure (HF), tolvaptan, a vasopressin V2 receptor antagonist, has been shown to im-
prove congestion. It has not yet been established whether these improvements may be associated with the he-
modynamic effects of tolvaptan.
Methods A total of 181 patients with advanced HF on standard therapy were randomized to double-blind treatment with
tolvaptan at a single oral dose (15, 30, or 60 mg) or placebo.
Results Tolvaptan at all doses significantly reduced pulmonary capillary wedge pressure (6.4  4.1 mm Hg, 5.7 
4.6 mm Hg, 5.7  4.3 mm Hg, and 4.2  4.6 mm Hg for the 15-mg, 30-mg, 60-mg, and placebo groups,
respectively; p  0.05 for all tolvaptan vs. placebo). Tolvaptan also reduced right atrial pressure (4.4  6.9
mm Hg [p  0.05], 4.3  4.0 mm Hg [p  0.05], 3.5  3.6 mm Hg, and 3.0  3.0 mm Hg for the 15-mg,
30-mg, 60-mg, and placebo groups, respectively) and pulmonary artery pressure (5.6  4.2 mm Hg, 5.5 
4.1 mm Hg, 5.2  6.1 mm Hg, and 3.0  4.7 mm Hg for the 15-mg, 30-mg, 60-mg, and placebo groups,
respectively; p  0.05). Tolvaptan increased urine output by 3 h in a dose-dependent manner (p  0.0001),
without changes in renal function.
Conclusions In patients with advanced HF, tolvaptan resulted in favorable but modest changes in filling pressures associated
with a significant increase in urine output. These data provide mechanistic support for the symptomatic improve-
ments noted with tolvaptan in patients with decompensated HF. (Heart Pressure Assessment Study With
Tolvaptan to Treat Congestive Heart Failure; NCT00132886) (J Am Coll Cardiol 2008;52:1540–5) © 2008 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.013s
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Casopressin plasma concentrations are known to be elevated
n patients with heart failure (HF) and left ventricular (LV)
ystolic dysfunction, and may lead to fluid retention and
emodynamic abnormalities (1–4). Inhibition of vasopres-
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alifornia; ¶Institutul de Boli Cardiovasculare si Transplant Professor Iliescu,
ucharest, Romania; #Medical Institute-Ministry of Interior, Sofia, Bulgaria;*Cardiovascular Clinical Studies, Boston, Massachusetts; and the ††Division of
ardiology, Northwestern University, Feinberg School of Medicine, Chicago, ain at the V2 receptors in the kidney through use of a
elective antagonist (tolvaptan) has been shown to be
ssociated with increased urine output and reductions in
ody weight in patients with HF (5–8). Recent studies also
llinois. All investigators and their institutions received support for this trial from
tsuka Pharmaceuticals Development and Commercialization. Drs. Udelson,
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ccepted August 4, 2008.
h
a
t
r
E
i
t
i
t
M
P
l
1
A
d
r
l
b
S
f
E
s
l
w
i
i
p
f
p
(
m
r
1
T
p
b
o
S
s
L
h
m
p
w
2
p
l
b
o
i
S
m
P
l
m
s
p
s
m
c
t
H
c
h
r
p
y
(
a
d
a
(
F
t
b
T
t
a
o
b
t
R
B
d
t
e
B
p
w
A
b
a
a
E
e
h
i
p
a
v
1541JACC Vol. 52, No. 19, 2008 Udelson et al.
November 4, 2008:1540–5 Tolvaptan’s Effect on Hemodynamics in HFave shown that the effects of tolvaptan on fluid volume are
ssociated with symptomatic improvements in patients hospi-
alized with worsening HF, without affecting outcomes (8).
Relatively little is known about the impact of vasopressin V2
eceptor antagonism on hemodynamic parameters. The
CLIPSE (EffeCt of toLvaptan on hemodynamIc Parameters
n Subjects with hEart failure) study was designed to evaluate
he hemodynamic effects of vasopressin V2 receptor inhibition
n a randomized, prospective, placebo-controlled trial of pa-
ients with advanced HF.
ethods
atient eligibility. Patients eligible for entry into the base-
ine evaluation phase of this trial were required to be more than
8 years of age and have symptomatic HF (New York Heart
ssociation functional class III or IV) of at least 3 months’
uration caused by LV ejection fraction 40%. Patients were
equired to be on standard background therapy for HF for at
east 1 month. Exclusion criteria included a supine systolic
lood pressure 90 mm Hg or serum creatinine 3.0 mg/dl.
tudy design. The protocol for this study and the consent
orm were approved by the Institutional Review Boards/
thics Committees at all participating sites, and all patients
igned an informed consent form. Patients entered a base-
ine inpatient phase in which a pulmonary artery catheter
as inserted. Patients received their daily dose of concom-
tant background medications at least 2 h before catheter
nsertion. Patients then entered a 2- to 20-h stabilization
eriod. After this stabilization period, final eligibility criteria
or entry into the randomized, double-blind treatment
hase included pulmonary capillary wedge pressure
PCWP) 18 mm Hg on 2 successive readings at least 10
in apart during the 2 h before study drug administration.
Patients eligible by baseline hemodynamic criteria were
andomized to receive a double-blind oral dose of placebo or
of 3 doses of tolvaptan (15, 30, or 60 mg) in a 1:1:1:1 ratio.
he doses of tolvaptan used in this study were selected to
rovide data on hemodynamics from the doses expected to
e used clinically in keeping with the EVEREST (Efficacy
f Vasopressin Antagonism in Heart Failure Outcome
tudy With Tolvaptan) trial of patients with decompen-
ated HF (7,8), as well as the SALT (Study of Ascending
evels of Tolvaptan in Hyponatremia) trials in patients with
yponatremia (9).
Hemodynamic and renal parameters and vital signs were
easured at multiple time points over an 8-h assessment
eriod. Background diuretics and other cardiac medications
ere held during this time period, and fluid was restricted to
50 ml every 2 h from the time of insertion of the
ulmonary artery catheter throughout the treatment period.
An independent technical review committee was estab-
ished to assess individual subject pressure tracing data in a
linded manner to determine evaluable datasets. A safety
versight committee monitored the safety of study subjects
n a blinded manner. ctatistical analysis. The pri-
ary efficacy end point was the
CWP peak change from base-
ine within 3 to 8 h after treat-
ent administration. A sample
ize of 45 patients per group (180
atients total) was calculated as-
uming a standard deviation of 5
m Hg for the PCWP peak
hange. The power of the study
o detect a difference of 3 mm
g was set at 80%.
Secondary efficacy parameters included area under the
urve (AUC) for the change from baseline PCWP and other
emodynamic parameters over an 8-h evaluation period and
enal and electrolyte parameters.
All patients with valid baseline PCWP and at least 1
ost-drug measurement were included in the primary anal-
sis of peak change in PCWP. An analysis of covariance
ANCOVA) model with terms of treatment and country,
nd with baseline PCWP as a covariate, was applied to the
ata of the primary efficacy variable for the 60-mg, 30-mg,
nd placebo groups. A comparison between a tolvaptan dose
30 or 60 mg) versus placebo was significant if both the
-test of the treatment effect of the ANCOVA model and
he t test of the contrast statement of the ANCOVA model
etween the tolvaptan dose and placebo were significant.
he comparison between tolvaptan 15 mg and placebo of
he primary efficacy variable was considered as secondary
nd was conducted by using a t test in a contrast statement
f ANCOVA. The area under the curve for change from
aseline in PCWP over 8 h post-dose was derived using the
rapezoidal rule.
esults
aseline characteristics of the population sample. The
emographic and baseline hemodynamic characteristics of
he study population are shown in Table 1. Patients were
nrolled at 48 study centers in the U.S., Romania, and
ulgaria. Of the 306 patients who were screened, 181
atients met the baseline hemodynamic entry criteria and
ere randomized into the double-blind treatment phase.
ngiotensin-converting enzyme inhibitors were used as
ackground therapy in 89.6% of placebo-treated patients
nd 87.8% of those randomized to tolvaptan, whereas 97.9%
nd 95.0% were on beta-adrenergic blockers, respectively.
ffect of tolvaptan on hemodynamic measurements. The
ffects of the vasopressin receptor antagonist tolvaptan on
emodynamic parameters in the study population are shown
n Table 2. These values represent the pre-specified end
oint using the peak change in these values between 3 to 8 h
fter study drug administration.
The pairwise comparisons of 15, 30, and 60 mg tolvaptan
ersus placebo each showed a statistically significant de-
Abbreviations
and Acronyms
ANCOVA  analysis of
covariance
AUC  area under the
curve
HF  heart failure
LV  left ventricular
PCWP  pulmonary
capillary wedge pressurerease in peak change in PCWP from 3 to 8 h post-dose
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Tolvaptan’s Effect on Hemodynamics in HF November 4, 2008:1540–5p  0.003, p  0.044, and p  0.033, respectively) (Fig.
A). The primary intention-to-treat statistical analysis for
he overall comparison among the treatment groups of
lacebo and of 30 and 60 mg tolvaptan, to assess distinct
esponses between these doses, approached statistical sig-
ificance (F-test, p 0.056). The AUC0-8h for the change
rom baseline in PCWP was also assessed. The 15-mg-
olvaptan group was the only tolvaptan dose group that was
tatistically significantly different from placebo, with the
0-mg group showing a statistical trend.
All tolvaptan doses produced statistically significantly
reater changes than placebo in peak change in pulmonary
rtery pressure (Table 2). Tolvaptan 15- and 30-mg doses
lso resulted in statistically significant reductions in peak
Baseline Demographics and Hemodynamics
Table 1 Baseline Demographics and Hemod
15 mg (n  44)
Demographics
Gender, n (%), male 32 (72.7)
Race, n (%), Caucasian 32 (72.7)
Age (yrs), mean (SD) 60.3 (11.7)
History of hypertension, n (%) 31 (70.5)
ICD, n (%) 10 (22.7)
CRT, n (%) 1 (2.3)
Diabetes mellitus, n (%) 23 (52.3)
Hypercholesterolemia, n (%) 29 (65.9)
Peripheral vascular disease, n (%) 7 (15.9)
Previous PTCA, n (%) 16 (36.4)
Previous CABG, n (%) 14 (31.8)
Previous MI, n (%) 22 (50.0)
Ischemic HF etiology, n (%) 24 (54.5)
Previous HF hospitalization, n (%) 37 (84.1)
Ejection fraction (%), mean (SD) 23 (8)
Diuretics, n (%) 42 (95.5)
Beta-blockers, n (%) 43 (97.7)
ACE-I/ARB, n (%) 39 (88.6)
Baseline
PCWP (mm Hg), mean (SE) 26.3 (1.1)
RAP (mm Hg), mean (SE) 14.6 (0.9)
PAP (mm Hg), mean (SE) 37.2 (1.5)
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin
resynchronization therapy; HF heart failure; ICD implantable cardiove
PCWP  pulmonary capillary wedge pressure; PTCA  percutaneous tra
Effects of Tolvaptan on Hemodynamic Paramete
Table 2 Effects of Tolvaptan on Hemodynam
Tolv
15 mg 30
PCWP, mm Hg 6.38 4.12† 5.67
Cl, l·min1·m2 0.32 0.48 0.50
PVR, dyn·s·cm5 40.94 109.13 98.71
SVR, dyn·s·cm5 237.5 476.5 344.7
PAP, mm Hg 5.60 4.23† 5.54
RAP, mm Hg 4.35 6.92† 4.30Values are mean  SD. *p  0.05, †p  0.01 versus placebo.
CI  cardiac index; PVR  pulmonary vascular resistance; SVR  systemichange in right atrial pressure as compared with placebo
Fig. 1B). No significant changes in cardiac index, pulmo-
ary vascular resistance, and systemic vascular resistance
ere observed after tolvaptan administration compared with
lacebo.
ffects of tolvaptan on renal and electrolyte parameters.
uring the 12-h study period, urine output in the
olvaptan-treated groups was substantially greater than that
n the placebo-treated group (Fig. 2A). The single dose of
olvaptan produced a dose-dependent increase in urine
utput (p  0.0001 for all tolvaptan groups vs. placebo).
rine osmolality was significantly reduced by all doses of
olvaptan relative to placebo (p  0.0001 for all tolvaptan
roups vs. placebo) (Fig. 2B). Free water clearance was also
ics
Tolvaptan
Placebo (n  48)mg (n  43) 60 mg (n  46)
36 (83.7) 36 (78.3) 40 (83.3)
31 (72.1) 31 (67.4) 34 (70.8)
9.7 (13.4) 61.0 (11.9) 58.9 (14.0)
28 (65.1) 29 (63.0) 33 (68.8)
21 (48.6) 19 (41.3) 16 (33.3)
7 (16.3) 6 (13.0) 6 (12.5)
15 (34.9) 16 (34.8) 17 (35.4)
30 (69.8) 30 (65.2) 29 (60.4)
6 (14.0) 11 (23.9) 8 (16.7)
13 (30.2) 15 (32.6) 11 (22.9)
19 (44.2) 10 (21.7) 14 (29.2)
27 (62.8) 23 (50.0) 26 (54.2)
20 (69.8) 25 (54.3) 26 (54.2)
33 (76.7) 38 (82.6) 44 (91.7)
23 (9) 24 (7) 24 (9)
43 (100.0) 45 (97.8) 48 (100.0)
38 (88.4) 44 (95.7) 47 (97.9)
37 (86.0) 40 (87.0) 43 (89.6)
4.3 (0.8) 25.0 (1.0) 24.8 (0.7)
2.6 (1.2) 13.2 (1.0) 12.6 (0.7)
5.3 (1.5) 36.9 (1.4) 37.6 (1.3)
r blocker; CABG  coronary artery bypass grafting; CRT  cardiac
fibrillator; MImyocardial infarction; PAP pulmonary artery pressure;
al coronary angioplasty; RAP  right atrial pressure.
rameters
Placebo60 mg
8* 5.71 4.35* 4.16 4.57
6 0.55 0.56 0.42 0.39
.67 108.3 117.02 42.04 117.09
.2 355.2 409.5 327.2 434.3
2* 5.24 6.11* 3.01 4.73
2* 3.49 3.61 3.03 3.01ynam
30
5
2
1
3
receptors
ic Pa
aptan
mg
 4.5
 0.4
 146
 330
 4.1
 4.0vascular resistance; other abbreviations as in Table 1.
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November 4, 2008:1540–5 Tolvaptan’s Effect on Hemodynamics in HFignificantly greater for all tolvaptan doses relative to pla-
ebo at all time points. Plasma osmolality showed a small
ut significant increase in all of the tolvaptan-treated groups
ompared with placebo (Fig. 3). Serum sodium levels
howed a dose-related modest increase compared with
lacebo (1.2  2.5 mEq/l, 3.3  3.9 mEq/l, 4.6  4.9
Eq/l, and 0.7  3.2 mEq/l for the tolvaptan 15-mg,
0-mg, 60-mg, and placebo groups, respectively), and po-
assium levels were not different from placebo in any of the
olvaptan dosing groups.
No significant changes in serum creatinine, blood urea
itrogen, serum potassium, and vital signs were observed
Figure 1 Mean Change from Baseline in PCWP and RAPs
(Top) Mean change from baseline in pulmonary capillary wedge pressure
(PCWP) out to 8 h after treatment administration. The pairwise comparisons of
15, 30, and 60 mg tolvaptan versus placebo each showed a statistically signif-
icant decrease in peak change in PCWP from 3 to 8 h post-dose, the pre-speci-
fied time period for assessment. (Bottom) Mean change from baseline in right
atrial pressure (RAP) in the 4 treatment groups. The tolvaptan 15- and 30-mg
doses resulted in statistically significant reductions in peak change in RAP as
compared with placebo.fter study drug administration.dverse events. Acute tolvaptan therapy was well tolerated
elative to placebo. Patient-reported adverse events in this
hort-term study occurred in 45.5%, 44.2%, 54.3%, and
3.3% of the 15-, 30-, and 60-mg tolvaptan and placebo
roups, respectively. The most commonly reported event
as catheter site pain, which occurred in 4.5% of the
olvaptan-treated patients and 6.3% of the placebo patients.
here were no drug-related deaths.
iscussion
he results of this prospective, multicenter, randomized,
ouble-blind, placebo-controlled trial suggest that antago-
ism of the vasopressin V2 receptor with a single dose of
olvaptan in patients with advanced HF results in favorable
lthough modest changes in hemodynamics associated with
Figure 2 Mean Change From Baseline
in Urine Volume and Osmolality
(Top) Mean change from baseline in urine volume in the first 8 h after treat-
ment administration. A dose-dependent increase in urine output was observed
among the tolvaptan-treated groups. (Bottom) Mean change from baseline in
urine osmolality in the first 8 h after dosing. Urine osmolality was significantly
reduced by all doses of tolvaptan relative to placebo (p  0.0001 for all
tolvaptan groups vs. placebo).
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Tolvaptan’s Effect on Hemodynamics in HF November 4, 2008:1540–5n increase in urine output. The magnitude of the enhanced
rine output was dose-dependent, whereas the changes in
lling pressures and pulmonary artery pressures were not
ependent on dose. Urine osmolality decreased and free
ater clearance increased after tolvaptan treatment com-
ared with placebo, consistent with antagonism of renal V2
asopressin receptors. These results occurred with no clin-
cally significant associated changes in electrolytes, blood
ressure, or heart rate. These data provide a potential
nderlying mechanism for the short-term clinical effects
oted in the EVEREST (Efficacy of Vasopressin Antago-
ism in Heart Failure Outcome Study With Tolvaptan)
rial (8).
In the EVEREST trial, 4,133 patients admitted to the
ospital with decompensated HF were randomized to
reatment with tolvaptan 30 mg per day or to placebo, in
ddition to standard therapy, soon after admission. More
atients receiving tolvaptan reported improvement in dys-
nea compared with patients randomized to placebo at day
after enrollment (p 0.001) (8). The data reported herein
rom the ECLIPSE trial suggest that the favorable changes
n symptomatic end points observed in the EVEREST trial
uring tolvaptan treatment were at least in part related to
he improved though modest changes in central hemody-
amics, which were in turn associated with the volume loss
rom the increased urine output.
In the contemporary era, several nonpeptide vasopressin
ntagonists have been studied. Conivaptan, a dual V1/V2
eceptor antagonist, was shown in a single-dose, dose-
anging trial, with a design similar to the present study, to
e associated with reductions in filling pressure and dose-
ependent increases in urine output in stable patients with
Figure 3 Changes in Plasma Osmolality
Mean change from baseline in plasma osmolality (OSM) in the 4 treatment
groups. A significant increase was observed in all of the tolvaptan dosing
groups (p  0.0005 for all tolvaptan groups vs. placebo at 4 h and later).dvanced HF (10). The data from the ECLIPSE trial show
Mimilar reductions in filling pressure and dose-dependent
ncrease in urine output, and in addition reductions in
ulmonary artery pressure. Taken together, the data suggest
hat the predominant clinical effects are mediated by V2
eceptor antagonism, even for the dual-receptor antagonist
onivaptan.
The magnitude of change in PCWP after a single oral
ose of tolvaptan in this study was modest relative to
lacebo. Indeed, the magnitude of PCWP reduction is less
han that reported for many vasoactive or other agents in
tudies of acute hemodynamic effects in HF patients, such
s tezosentan (11,12), levosimendan (13), or nesiritide (14).
owever, a greater magnitude of PCWP change may come
ith a cost in terms of greater risk of hypotension. An excess
f hypotension has not been reported in the published
olvaptan data, now involving several thousand patients with
ecompensated HF (7,8).
To the extent that the results from the ECLIPSE trial in
atients with stable though advanced HF can be extrapo-
ated to the EVEREST population, the data suggest that
ven modest short-term reduction in PCWP can be asso-
iated with identifiable improvement in dyspnea, using
asopressin receptor antagonism. Given the modest PCWP
eduction, it is possible that the slight increase in plasma
smolality observed in this data set might also contribute to
elief of dyspnea though osmotic mechanisms (as suggested
y studies of high-dose furosemide with hypertonic saline in
ecompensated HF patients [15]) possibly resulting in
iminution of interstitial lung water.
There are limitations to this dataset and to the conclu-
ions that may be drawn from it. The patients in this study
ad advanced symptomatic HF and were selected to have
bnormal baseline hemodynamics. Thus the generalizability
o all patients with decompensated HF, in whom treatment
ith tolvaptan would potentially be started concomitant
ith intravenous diuretics and other acute therapies, is not
ertain. The reported safety issues and effects on renal and
lectrolyte parameters in this study are the consequence only
f single-dose administration. The safety of repeated dosing
hronically on all of these parameters has been reported in
he large EVEREST patient database (7,8).
Hence, antagonism of the vasopressin V2 receptor with a
ingle dose of tolvaptan in patients with advanced HF
esults in favorable although modest changes in hemody-
amics associated with a dose-dependent increase in urine
utput, and an increase in free water clearance, with no
hort-term changes in potassium or renal function. The
esults provide a potential mechanistic explanation for the
hort-term favorable effects of tolvaptan on symptoms such
s dyspnea in patients with decompensated HF as reported
n the EVEREST trial.
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